Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 3/20 | 0.47 |
| ▸ | HTR2A | P28223 | 3/20 | 0.47 |
| ▸ | HTR7 | P34969 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.43 |
| ▸ | BRAF | P15056 | 2/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 5/20 | 0.40 |
| ▸ | DRD2 | P14416 | 4/20 | 0.40 |
| ▸ | DRD3 | P35462 | 4/20 | 0.40 |
| ▸ | P2RY1 | P47900 | 5/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3703082 | 0.92 | DRD4 (0.45) | HTR1AHTR2AHTR7HTR6DRD4 | |
| SCHEMBL15053550 | 0.92 | RAB9A (0.42) | HTR1AHTR2AHTR7RAB9ASTING1 | |
| SCHEMBL3709379 | 0.92 | HTR1A (0.43) | HTR1AHTR2AHTR7RAB9ABRAF | |
| SCHEMBL3708118 | 0.91 | DRD4 (0.47) | HTR1AHTR2AHTR7STING1BRAF | |
| SCHEMBL3709385 | 0.91 | DRD4 (0.47) | HTR1AHTR2AHTR7RAB9ASTING1 | |
| SCHEMBL3697641 | 0.91 | BRAF (0.47) | HTR1AHTR2AHTR7RAB9ASTING1 | |
| SCHEMBL3705882 | 0.91 | BRAF (0.49) | HTR1AHTR2AHTR7STING1BRAF | |
| SCHEMBL3702250 | 0.90 | HTR2A (0.52) | HTR1AHTR2AHTR7RAB9AHTR6 | |
| SCHEMBL3709473 | 0.89 | P2RY1 (0.41) | HTR1AHTR2AHTR7BRAFHTR6 | |
| SCHEMBL3704132 | 0.89 | DRD4 (0.49) | HTR1AHTR2AHTR7RAB9AHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8648086-B2 | 5,6-bicyclic heteroaryl-containing urea compounds as kinase inhibitors | ASCEPION PHARMACEUTICALS, INC. (CN) | 2014-02-11 | — | — | US | claimed |
| US-20120122895-A1 | 5,6-BICYCLIC HETEROARYL-CONTAINING UREA COMPOUNDS AS KINASE INHIBITORS | JIANG, SHAN | 2012-05-17 | — | — | US | claimed |
| CN-102066372-A | 5, 6-membered heteroaryl bicyclic compounds containing a urea group as kinase inhibitors | ASCEPION PHARMACEUTICALS INC | 2011-05-18 | — | — | CN | claimed |
| CN-102066372-B | 5, 6-membered heteroaryl bicyclic compounds containing a urea group as kinase inhibitors | ASCEPION PHARMACEUTICALS INC | 2014-09-17 | — | — | CN | disclosed |
| US-8648086-B2 | 5,6-bicyclic heteroaryl-containing urea compounds as kinase inhibitors | ASCEPION PHARMACEUTICALS, INC. (CN) | 2014-02-11 | — | — | US | disclosed |
| US-20120122895-A1 | 5,6-BICYCLIC HETEROARYL-CONTAINING UREA COMPOUNDS AS KINASE INHIBITORS | JIANG, SHAN | 2012-05-17 | — | — | US | disclosed |
| CN-102066372-A | 5, 6-membered heteroaryl bicyclic compounds containing a urea group as kinase inhibitors | ASCEPION PHARMACEUTICALS INC | 2011-05-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122895-A1 | 5,6-BICYCLIC HETEROARYL-CONTAINING UREA COMPOUNDS AS KINASE INHIBITORS | FLT3, CSF1R, EPHA2 | HTR1A 1518/4885HTR2A 1776/4885HTR7 1326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.